**Supplementary table 1: Disease subtype by commencement of biologic**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| % (n) | **IFX Originator (IFX-O)** | **IFX Biosimilar****(IFX-B)** | **Adalimumab** | **Total** |
| **Crohn’s disease** | 61% (129) | 30% (63) | 9% (19) | **211** |
| Active luminal | 60% (99) | 29% (48) | 11% (18) | **165** |
| Fistulating | 92% (11) | 8% (1) | 0 | **12** |
| Severe perianal | 56% (14) | 40% (10) | 4% (1) | **25** |
| Not known | 67% (4) | 33% (2) | 0 | **6** |
| Other | 33% (1) | 66% (2) | 0 | **3** |
|  |  |  |  |  |
| **Inflammatory Bowel Disease - Unclassified** | 70% (14) | 25% (5) | 5% (1) | **20** |
| Acute severe | 60% (6) | 30% (3) | 10% (1) | **10** |
| Chronic refractory | 78% (7) | 22% (2) | 0 | **9** |
| Other | 100% (1) | 0 | 0 | **1** |
|  |  |  |  |  |
| **Ulcerative Colitis** | 68% (32) | 30% (14) | 2% (1) | **47** |
| Acute severe | 75% (18) | 25% (6) | 0 | **24** |
| Chronic refractory | 61% (14) | 35% (8) | 4% (1) | **23** |
| **Total** | **63% (175)** | **29% (82)** | **8% (21)** | **278** |

IBD = inflammatory bowel disease.